Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 8/20 | 0.52 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497482 | 0.82 | CDC7 (0.51) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL2500617 | 0.80 | CDC7 (0.59) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL2497851 | 0.78 | PLK1 (0.46) | CDC7DBF4TRPM8MAPTLMNA | |
| SCHEMBL12850096 | 0.74 | TGFBR1 (0.52) | KDM4EMEN1KMT2ALMNA | |
| SCHEMBL15049060 | 0.69 | TRPM8 (0.80) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL15049177 | 0.69 | TRPM8 (0.76) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL26638915 | 0.69 | CDC7 (0.65) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL31318855 | 0.67 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL6338322 | 0.67 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL15049004 | 0.67 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813613-B1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8030327-B2 | 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle | MDS K.K. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | CDC7 3024/4885DBF4 1830/4885TRPM8 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.